{"id":399869,"date":"2020-12-15T08:33:11","date_gmt":"2020-12-15T13:33:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399869"},"modified":"2020-12-15T08:33:11","modified_gmt":"2020-12-15T13:33:11","slug":"arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/","title":{"rendered":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;text-align:left\">rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines<\/li>\n<li style=\"margin-bottom:4pt;text-align:left\">rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy<\/li>\n<li style=\"margin-bottom:4pt;text-align:left\">Topline trial data anticipated in the second quarter of 2021<\/li>\n<li style=\"margin-bottom:4pt;text-align:left\">Data from this development program will also inform potential development in additional RNA virus-associated diseases<\/li>\n<\/ul>\n<p align=\"justify\">WESTMINSTER, Colo., Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=djlEe1Onk8IeYJez3HnvnDlD1fOp6sBOidp6zirb8G3vOXCc9i9mBLS1lCqDDT2r4NJYwmtNP7KBowaK2PHPfg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ARCA biopharma, Inc.<\/a> (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VPz5BUMjfAPTbP3QzLQ9uVVB_Sa296gTyWw9apDOz3UOpg-WmaCHgRKewQ9RBD-fj-_Svd-FTTrBYf7ijc25vozRAYa9PG4YSDquJCHybDV-_7OCrltWjCzJbShvQLEi\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ASPEN-COVID-19<\/a>, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19. The first patient was enrolled at the University of Colorado Hospital on December 10, 2020, with a total of 5 patients randomized to date. The Company currently anticipates topline trial data from this Phase 2b clinical trial in the second quarter of 2021.<\/p>\n<p align=\"justify\">\u201cThere is a critical need for safe, efficacious treatments in hospitalized COVID-19 patients, and we believe this need will continue even with potentially effective vaccines available,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BYVePGtjayO-nn83pFTqfZguaiEJoi4i27oueeSWYrAQ8MB2Ugf4vDsqRu1NtFeyIaT6OK0N-zLc4gCh0WkWnJyThM4dIbOX5ONvm-053M4fPKinrvURO58HTBVmpVbs\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr. Michael Bristow<\/a>, ARCA\u2019s President and Chief Executive Officer, who is also an <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L0CsyFB27jjk8qEUejsMKDZTdde8VjDMXnd-P2AR_JA4k1ngFXUekf_eZo6qFZC1Fj9jdc3Dz6WJMlxCYfWdP-3mlDLF9qJdZb0Wntx67WQ8CMuudreqnDZg-bwtk8xMlLmEcLnr9UCwbYMTtFp70JImJhCYhyJsuLqufN-wxworjJ7VhijQoGag1RQsC5zs9MUlgEKEAmgKgLzkn2M1IF8Ky8pf4F0mrshV3qAQqGjA8_gE44RfJsDd7aOPyJqbAQFqAv03V2_tUP97UA9tSulugfM0uRb209SYW5DgzFg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">American Heart Association (AHA) funded COVID-19 investigator<\/a>. \u201cWe believe rNAPc2\u2019s combination of anticoagulant, anti-inflammatory and antiviral effects may favorably impact clinical recovery of patients hospitalized with COVID-19, and we look forward to completing the ASPEN-COVID-19 trial evaluating rNAPc2\u2019s potential efficacy in this patient population.&#8221;<\/p>\n<p align=\"justify\">ASPEN-COVID-19 Phase 2b is a randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin prescribed per local standard of care in approximately 100 hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level. The primary endpoint of the trial is safety and change in D-dimer level from baseline to Day 8 relative to standard of care heparin. D-dimer is a biomarker commonly used for assessing coagulation activation, which is elevated in approximately 50% of hospitalized COVID-19 patients and is directly associated with adverse clinical outcomes.<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WDzukUSX6wspkgX0wy5tNSLLVYX-3ZULe-jkR9vJKsvmPH76UthRjuVXFxLRaP6DqpQ7nMS-Q1nwLDCvmzFKWMhMIcnHApG5a48_1WXQ16N5Tj5BJ54vf5i6MbsZXOS_MR3QQ-4Sl6O91-r9WWQTXagmCQAMgrYe4Q0DDv8tMTA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr. Wolfram Ruf<\/a>, Scientific Director of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HVoewOXI8ef3eH9Zzj5GFRD72AWMwm4IEqQOXeu-ZnQZd5tPU6BTvQrz1CzdKL3WIkBRoCxnFwc55abx64lig5Mwp8CmNXnU78glMzOKpt9-au4oGsriZ6poJaZ-WllP6-k_b1pULukZsJYgOYAaBQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Center for Thrombosis and Hemostasis<\/a> at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_4eCwhe3wnuNythJoRNK-NjqPfOTIWkBKavzgdKGGh24zzalQAuSEJBFM96QtpQ5WskOnWVn-Zhw2MLInw8qJzPNQ2I2q7ShaysBy4JLAl_CYZ9NTt5QtrPMGn5MYx-Hfg5yLlWXVdF_Z0jUHPhK3Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Johannes Gutenberg University Medical Center<\/a> Mainz, Germany, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9ITjf-uCvynP6WLiTvMf2N8J52TL8B4u6qSlLp_f-UAre0KxSUc55LVJI4xu_GKTzF8vLIpaTOj6gmNBeuwSPA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Professor<\/a> at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eQhgSK42A2yjxr1AJHvdxJu1ooRn23t_CpwmV9bDQ-P-9Be1RTYxes0NZ8a43z-VfLJRLVrDQUwunpo2QjUcaQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Scripps Research<\/a>, La Jolla, CA, commented, \u201cThe clinical course of some patients with COVID-19 is complicated by a virus-triggered coagulopathy that includes thrombotic events and inflammatory processes, thought to be mediated in part by tissue factor production. Because rNAPc2 is a potent tissue factor inhibitor, it has anticoagulant with anti-inflammatory and antiviral properties. With its properties in modulating the tissue factor pathway, rNAPc2 has the potential to be a uniquely beneficial therapy for patients hospitalized with COVID-19, and potentially other RNA virus associated diseases as well.\u201d<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ebJjehnU1fPh7_Z8_5zLOtLZf7gKKQ7sKKozpkro0DHoyylgKJI22GYkAY_iL6qAOFFLG44D0cceKGn2stMbN-iUX1q8R0AeFeASVerAqvB4Cx2kgE6dGCw0K5Pzlrk_\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr. Marc Bonaca<\/a> MD MPH, Executive Director of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YkDvOOaq294lHun-ZGpoJAnB0fImvJS2QfSOEGNOsSm-K9hKn88wg3duRr0hohAUoRhZ7n7lPUjxoq03w5Ps4nHAvMyYMxfqrjV9b28ziNE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">CPC Clinical Research<\/a> and the Director of Vascular Research at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cUXBJ7Fr1TfpZngNA2qyxEhZz5MsI689Ck7m91KEtsHL4Q_wgQHNWe7oZvnY_xkiQ-pGeykp0imzoB1_XFYht_9xjuwQ7GJS75ifHSM3iyTR_9i7VhrmUhrOhkXYyM9ZwQh6iAS9oEZflKVqwbFc5w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">University of Colorado School of Medicine<\/a>, Aurora, Colorado commented, \u201cCoagulopathy has now been well described as a core malignant feature of COVID-19, as well as other severe viral infections, but we are learning that just simply increasing the intensity of anticoagulation using traditional therapies may not be the optimal approach both for efficacy and for bleeding risk. Targeted inhibition of tissue factor, which plays a key role in the complex interplay of coagulation, inflammation, and infection, holds promise to potentially improve outcomes. The ASPEN-COVID-19 study will provide critical data as to the role of rNAPc2 in this setting as well as other viral and inflammatory conditions characterized by tissue factor mediated coagulopathy.\u201d<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xTck7SDQcp4VLB0wBTyUVls_9f7RCwtVm_ftWjGuxWngPQuFmuFoClFGCMMPg6R-1DdcK-vj6F7b09JCHGo9MVcUtne60IO-xg6-bg330S4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">U.S. Food and Drug Administration<\/a> (FDA) has designated the investigation of rNAPc2 as a potential treatment for COVID-19 as a Fast Track development program. ARCA believes that rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19.<\/p>\n<p align=\"justify\">\n        <strong>About rNAPc2 (AB201)<\/strong><br \/>\n        <br \/>rNAPC2 is a small recombinant protein being developed as a potential treatment for RNA virus-associated diseases, initially focusing on COVID-19.\u00a0 rNAPC2 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives rNAPC2 a combination of anti-coagulant, anti-inflammatory and anti-viral properties, and therefore the potential to be effective in addressing the impact of viral infections from multiple pathways.\u00a0\u00a0rNAPC2\u00a0 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including in clinical studies for prevention of venous and arterial thrombosis, where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system and other aspects of the immune response, resulting in serious complications.\u00a0 Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that rNAPC2 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating rNAPC2 as a treatment for COVID-19 and other RNA virus associated diseases.<\/p>\n<p align=\"justify\">\n        <strong>About ARCA biopharma<\/strong><br \/>\n        <br \/>ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing Gencaro\u2122\u00a0(bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential pharmacogenetic treatment for atrial fibrillation in patients with heart failure. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5w707xfr0oc0Hi6UQuDJnEQ_bw7QAegFGIiA_Lm07-zClS7IC2QM9fqe2U8nodvV1HMG0xDD-hPZ6WR8WzYMcg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.arcabio.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6qng5Q3WYIY9NsZJqRKr-8QwLWvtjpa9v9x80VMdtDU3e-uqAyEJ-1kjmOJP3K91yk6QxslG0oA87MBJXWPzbmEBZonXbhSfE1U4rVFuGFKAQDr98msTvo-mtG8dzx_o\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>\n        <em>This press release contains &#8220;forward-looking statements&#8221; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding potential future development plans for rNAPc2 (AB201), the expected features and characteristics of rNAPc2, the anticipated development timeline for rNAPc2, rNAPc2\u2019s potential to treat COVID-19, or any other RNA virus associated disease, whether rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19 Associated Coagulopathy and the potential future treatment options and needs for patients with COVID-19<\/em><br \/>\n        <em>. <\/em><br \/>\n        <em>Such statements are based on management&#8217;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA\u2019s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of rNAPc2 or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA\u2019s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA\u2019s filings with the Securities and Exchange Commission, including without limitation ARCA\u2019s annual report on Form 10-K for the year ended December\u00a031,\u00a02019, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"both\">\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Derek Cole<br \/>720.940.2163<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2avQKPwmFImNcWtHPme8nCP3aWm_fUeq1FOR_7edRVaesCQOmMXpot_mpVRiDZOrFXUXrsCH5gvmjgSBBPrSTlckDHmG4H9vW2TrP7CVdjw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">derek.cole@arcabio.com<\/a><\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y1vNl0xr2OuGmq7gkmStmTZjmF4jua7zrj2qbw9PKW1ME6-Gj4zMxJYdZv7cL6-_aDLvzpSySvAmWB7AG0A8JltcQw5PRv57XgVZoFsdC0-jAsi9fanj6f1m561ukMUfPCD235m3BPDQEmdJfBWKJLOIpuIpG0dO5GyWWBqDuar5ca9QLQ3vYDG1r49jP4Df7Fza0h4TA1qVhQko87MCGGylI03dHzavGvDgeXjkW69fp50szEawiulHo1xk2pg4Ow5au3huft4KMK_XIuFe3g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/af496e97-20da-420a-bf93-e51b3a3ed740<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ca404c39-0e38-47c2-bbcb-359619692dd1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 Data from this development program will also inform potential development in additional RNA virus-associated diseases WESTMINSTER, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19. The first patient was enrolled at the University of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 Data from this development program will also inform potential development in additional RNA virus-associated diseases WESTMINSTER, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19. The first patient was enrolled at the University of &hellip; Continue reading &quot;ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T13:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19\",\"datePublished\":\"2020-12-15T13:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/\"},\"wordCount\":1263,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/\",\"name\":\"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\",\"datePublished\":\"2020-12-15T13:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk","og_description":"rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 Data from this development program will also inform potential development in additional RNA virus-associated diseases WESTMINSTER, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19. The first patient was enrolled at the University of &hellip; Continue reading \"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T13:33:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19","datePublished":"2020-12-15T13:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/"},"wordCount":1263,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/","name":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=","datePublished":"2020-12-15T13:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE5OSMzODgxNTAyIzIwMDkxNDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-ab201-as-a-potential-treatment-for-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}